ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2658

Cognitive Symptoms and Associated Disease and Non-Disease Related Factors in Patients with Systemic Lupus Erythematosus : A Longitudinal Study

Yang Gao, Yi Lo and Mo Yin Mok, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Anxiety, Cognitive dysfunction, depression, longitudinal studies and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women's Health, Cardiovascular and CNS

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cognitive impairment is commonly reported in patients with systemic lupus erythematosus (SLE). Its associated disease and non-disease related factors have been inconsistently reported.

Objective: To examine cognitive symptoms and its relation to disease related factors including disease activity, antiphospholipid antibody, previous neuropsychiatric history (NPSLE) and non-disease related factors such as anxiety and depression over time.

Methods: Cognitive symptoms inventory (CSI) was used to measure perceived cognitive impairment serially at 3 time-points 12 months apart. Disease activity was measured by SLEDAI. Depressive and anxiety symptoms were measured by HADS-D and HADS-A respectively.

Results: 304 SLE patients were recruited at baseline (T0) among whom 144 had first re-evaluation (T1) and 34 had second re-evaluation (T2) at 12-month interval. Majority (73.5%, 25/34) of patients had stable CSI whereas 5.9% (2/34) of patients had persistently worsened CSI over 24 months. At T0, multivariate analysis revealed that higher CSI was associated with history of NPSLE (p=0.005) and psychiatric disease (p=0.04), higher HADS-A (p<0.001) and HADS-D (p<0.001) scores. CSI of active patients (SLEDAI>6) was not different from inactive patients and did not change despite regression of disease activity in 12 months. There was no difference in CSI between T0 and T1 regardless of history of NPSLE, psychiatric history, change in depressive status at T1 (HADS-D>11 as cutoff) but CSI was significantly different in patients who demonstrated change in anxiety status at T1 (HADS-A>11 as cutoff) (p=0.03). Multivariate linear regression analysis revealed change in HADS-A as the only significant predictive factor of change in CSI over time (β=0.774, 95% CI 0.43 – 1.12, p<0.001).

Conclusion: 5.9% of unselected SLE patients reported persistent cognitive symptoms. Patients with history of NPSLE and psychiatric illness, high anxiety and depressive symptoms had worse CSI than those without these conditions. CSI was sensitive, but modestly, to change in anxiety symptoms over time.


Disclosure:

Y. Gao,
None;

Y. Lo,
None;

M. Y. Mok,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cognitive-symptoms-and-associated-disease-and-non-disease-related-factors-in-patients-with-systemic-lupus-erythematosus-a-longitudinal-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology